Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153879 | 0.99 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6155708 | 0.99 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6155768 | 0.97 | ALDH1A1 (0.43) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL8102943 | 0.80 | POLB (0.41) | ALDH1A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL7157105 | 0.77 | CYP1A2 (0.37) | ALDH1A1MEN1KMT2AL3MBTL1CYP1A2 | |
| SCHEMBL6154092 | 0.74 | PTGS2 (0.47) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6154647 | 0.73 | NPBWR1 (0.39) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6153992 | 0.73 | AMY1A (0.46) | ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL5549224 | 0.73 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL6155298 | 0.73 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | claimed |
| EP-1077694-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | claimed |
| US-6083989-A | ADMINISTERING TO THE PATIENT SUFFERING FROM INFLAMMATORY BOWL MOVEMENT AN N-SUBSTITUTED ARYL NITRON COMPOUND OR SALT | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | claimed |
| WO-1999059576-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | claimed |
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | KELLEHER JUDITH A (US) | 2005-06-09 | — | — | US | disclosed |
| EP-1025079-B1 | $g(a)-ARYL-$i(N)-ALKYLNITRONES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | RENOVIS INC (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1077694-B1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | RENOVIS INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | RENOVIS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6441032-B1 | TREATING SYSTEMIC LUPIS AND MULTIPLE SCLEROSIS | CENTAUR PHARMACEUTICALS, INC. | 2002-08-27 | — | — | US | disclosed |
| US-6433008-B1 | TREATING PARKINSON*S, ALZHEIMER*S, AUTOIMMUNE AND RHEUMATIC DISEASES; HUMAN IMMUNODEFICIENCY VIRUS (HIV) DEMENTIA, AND INFLAMMATION | CENTAUR PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6258852-B1 | NITRONE COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASE | CENTAUR PHARMACEUTICALS, INC. | 2001-07-10 | — | — | US | disclosed |
| EP-1077694-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| US-6083989-A | ADMINISTERING TO THE PATIENT SUFFERING FROM INFLAMMATORY BOWL MOVEMENT AN N-SUBSTITUTED ARYL NITRON COMPOUND OR SALT | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-07-04 | — | — | US | disclosed |
| US-6046232-A | THERAPEUTICS FOR TREATING AND/OR PREVENTING NEUROLOGICAL, AUTOIMMUNE AND INFLAMMATORY CONDITIONS IN MAMMALS AND AS ANALYTICAL REAGENTS FOR DETECTING FREE RADICALS | CENTAUR PHARMACEUTICALS, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999059576-A1 | ARYL NITRONE THERAPEUTICS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | CENTAUR PHARMACEUTICALS, INC. (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124691-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | ALDH1A1 410/4885KDM4E 3089/4885MEN1 2880/4885 |
| US-20030087957-A1 | Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same | NLN, NAT1, SNCA | ALDH1A1 499/4885KDM4E 2921/4885MEN1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.